Pepgen announces pricing of $80.1 million underwritten offering of common stock

Boston, feb. 07, 2024 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 7,530,000 shares of its common stock at a price to the public of $10.635 per share. the aggregate gross proceeds to pepgen from this offering are expected to be approximately $80.1 million, before deducting underwriting discounts and commissions and offering expenses payable by pepgen. the offering is expected to close on or about february 9, 2024, subject to customary closing conditions.
PEPG Ratings Summary
PEPG Quant Ranking